According to GlobalData’s medical device pipeline database, 343 Cardiac Marker Tests devices are in various stages of development globally. GlobalData’s report Cardiac Marker Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 103 are in active development, while the remaining 240 are in an inactive stage of development. There are 61 products in the early stages of development, and the remaining 42 are in the late stages of development.
A cardiac marker test is a biomarker test used to diagnosis cardiac diseases. Cardiac marker tests are categorized into lab-based biomarker and point of care biomarker tests. Laboratory Tests Any tests that require transporting of patient samples to a laboratory, including those with rapid turnaround times, are defined as being laboratory or lab-based tests. For this Cardiac Marker tests model, lab-based tests include laboratory troponin tests, laboratory BNP tests, and CK-MB laboratory tests. Point Of Care Tests Point of Care Testing (POC) is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care. POC is typically performed by non-laboratory personnel and the results are used for clinical decision making. POC has a range of complexity and procedures that vary from manual methodologies to automated analyzers. POC devices are often ‘handheld’ or may be small portable analyzers. For this Cardiac Marker tests model, POC tests include POC troponin tests, POC BNP tests, and other POC tests.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Cardiac Marker Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Cardiac Marker Tests devices. Overall, most of these Cardiac Marker Tests pipeline devices are being developed by private entities.
Key players involved in the active development of Cardiac Marker Tests include Upstream Medical Technologies, Siemens Healthcare Diagnostics, Abbott Diagnostics, China Medical Technologies, Roche Diagnostics International, Guangzhou Wondfo Biotech, Ortho Clinical Diagnostics, Cavadis, Beckman Coulter and Abionic.
For a complete picture of the developmental pipeline for Cardiac Marker Tests devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
